Cytomedix to Showcase AutoloGel System at the 18th Annual Scientific Meeting of the International Society of Hair Restoration Surgery

/ Source: GlobeNewswire

GAITHERSBURG, Md., Oct. 20, 2010 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (NYSE Amex:GTF), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, will be showcasing its AutoloGel™ System at the 18th Annual Scientific Meeting of the International Society of Hair Restoration Surgery (ISHRS) being held from October 20-24, 2010 in Boston.

The AutoloGel System, the only PRP system with FDA clearance for wound management, will be highlighted at Cytomedix's Exhibit Booth #51 from October 21-23 before an audience of more than 800 physicians and surgeons and 150 surgical assistants who specialize in hair restoration. 

In a previously published article in Hair Transplant Forum International, the bi-monthly publication of ISHRS, renowned hair restoration specialist, Robert J. Reese, D.O., noted that, "Relating to hair restoration, the application of PRP has been evaluated as a treatment to both speed wound healing and foster hair growth.  Both of these endpoints relate to the delivery of growth factor, cytokine and chemokine activities, and based upon available past and present data, this author suggests that PRP containing physiologic concentrations of platelets is most appropriate."

"The surgical hair restoration market offers an excellent opportunity for Cytomedix as it is a private-pay indication. We are looking forward to discussing our AutoloGel product with hair restoration specialists who want to enhance clinical outcomes for their patients," said Martin P. Rosendale, President and Chief Executive Officer of Cytomedix. 

"We have long understood the underlying clinical rationale for AutoloGel's benefits in wound care and are pleased that Dr. Reese's outcomes confirm that physiologically relevant concentrations of AutoloGel's PRP may speed the healing and foster hair growth following hair restoration surgery," concluded Mr. Rosendale.

Subsequent to his authorship of the above mentioned journal article, Dr. Reese became a paid consultant to the Company in the area of hair restoration surgery.  

About The International Society of Hair Restoration Surgery

The International Society of Hair Restoration Surgery is a non-profit medical association composed of more than 800 physicians and surgeons and 150 surgical assistants who specialize in hair restoration. Since its incorporation in 1993, a renaissance in hair transplantation surgery was set into motion by the ISHRS. The multidisciplinary, international membership of the ISHRS became a critical mass for an explosion of innovation in hair transplantation surgery. The Annual Meeting is a highlight of the year in which the top minds in HRS come together to advance the art and science of hair restoration surgery.

About Cytomedix, Inc.

Cytomedix develops, sells and licenses regenerative biological therapies primarily for wound care, inflammation and angiogenesis. The Company markets the AutoloGel™ System, a device for the production of platelet rich plasma (PRP) gel derived from the patient's own blood for use on a variety of exuding wounds; the Angel® Whole Blood Separation System, a blood processing device and disposable products used for the separation of whole blood into red cells, platelet poor plasma (PPP) and PRP in surgical settings; and the activAT® Autologous Thrombin Processing Kit, which produces autologous thrombin serum from PPP. The activAT® kit is sold exclusively in Europe and Canada, where it provides a completely autologous, safe alternative to bovine-derived products. The Company is pursuing a multi-faceted strategy to penetrate the chronic wound market with its products, as well as opportunities for the application of AutoloGel™ and PRP technology into other markets such as hair transplantation and orthopedics while actively seeking complementary products for the wound care market. Cytomedix also seeks to monetize other product candidates in its pipeline through strategic partnerships, out-licensing or sale. Most notably is its anti-inflammatory peptide (designated CT-112) that has shown promise in preclinical testing.  Additional information regarding Cytomedix is available at .

Safe Harbor Statement

Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, viability and effectiveness of the Company's sales approach and overall marketing strategies, the outcome of development or regulatory review of CT-112, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, and Cytomedix's ability to execute on its strategy to market the AutoloGel™ System as contemplated, the Company's ability to successfully integrate the Angel® and activAT® product lines into its existing business, to assume and satisfy certain liabilities related to the Angel® and activAT® product lines, or its ability to service the deferred payments related to the acquisition of the Angel® and activAT® product lines. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

CONTACT: Cytomedix, Inc. David Jorden, Executive Board Member Martin Rosendale, CEO Andrew Maslan, CFO (240) 499-2680 Lippert/Heilshorn & Associates Anne Marie Fields (212) 838-3777 Bruce Voss (310) 691-7100